Vraylar | Community Health

Vraylar, also known as cariprazine, is an atypical antipsychotic medication developed by [[gedeon-richter|Gedeon Richter]] for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. It is characterized by its unique mechanism of action, primarily acting as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Vraylar is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. The medication is taken orally and has a distinct side effect profile, including nausea, mild sedation, fatigue, and dizziness. With its approval in the United States in 2015 and subsequent approvals in other countries, Vraylar has become a significant player in the mental health treatment landscape, offering a new option for patients and healthcare providers. As of 2025, Vraylar is covered by patents until 2029, and its cost varies depending on the region and availability of generic versions.